Summary
Novo Nordisk is seeking a court injunction to block Eli Lilly's weight-loss drug advertisements, alleging that Lilly's ads mislead consumers with outdated studies and inaccurate comparisons. Eli Lilly denies the claims, asserting its advertising is truthful, as both companies compete in the growing market for obesity and diabetes treatments.